Beyond its Covid vaccination, Moderna offers further benefits.
The biotech business revealed encouraging results from three experimental vaccines against different viruses. According to the corporation, such photos are being moved to final stage studies.
With the global demand for Covid shots declining, Moderna desperately needs to have various products on the market, and this update takes them one step closer to that goal. The company's sole product that is sold commercially is the Covid jab.
The vaccination has long been associated with Moderna's stock, which saw a nearly 45% decline in value last year. However, following the developments, the company's shares closed 3% higher.
During its fifth annual "Vaccines Day," an investor event in Boston centred on the company's vaccine portfolio, Moderna will map out its post-Covid future.
The anticipated total addressable market for infectious disease injections in that industry is $52 billion, comprising of $27 billion for respiratory vaccines and over $25 billion for latent doses and other immunisations.
Latent viruses are a type of virus that can exist inside individuals for extended periods of time without showing any symptoms, but they can eventually "reactivate" and cause major health issues. In an interview, Moderna CEO Stéphane Bancel stated that they represent a significant unmet demand that Moderna can address.
"Once those viruses enter your body, they stay there forever," he stated, noting that several of the latent viruses, including several that Moderna is aiming to eradicate, have no recognised vaccinations.
At the presentation on Wednesday, the business will provide updated clinical trial data on the three vaccinations, some of which are against latent viruses.
A vaccination against the highly contagious norovirus, which causes vomiting and diarrhoea, a vaccination against the Epstein-Barr virus, a common herpes virus that can cause contagious infections and is linked to certain cancers, and a vaccination against a virus that causes shingles and chickenpox are among those vaccinations.
Additionally, Moderna will talk about other developments in its vaccine business. The business stated that it plans to share data on two of the five more injections it has in late-stage clinical studies this year. This contains a shot against the cytomegalovirus, or CMV, another prevalent herpes virus, as well as a combo vaccine against Covid and the flu.
A vaccine against the respiratory syncytial virus, or RSV, is one of the other vaccines under late-stage development and is anticipated to receive regulatory approval in the United States in May.
A revised and enhanced version of Moderna's Covid shot is also included. In a late-stage clinical trial, the company said on Tuesday that its "next-generation" Covid injection elicited a better immune response against the virus than its existing vaccine on the market.
The flu vaccine developed by the business is also undergoing phase three trials.
Additionally on Wednesday, Moderna said that it has just joined up with Blackstone Life Sciences, a division of The Blackstone Group that provides private equity, to provide capital for both development and commercialization. Moderna's flu vaccination programme will be advanced with up to $750 million from Blackstone, with low single-digit royalties and "a return based on commercial milestones."
Bancel claimed that the Covid vaccine's messenger RNA platform "is working so well" against various illnesses. The way mRNA technology functions is by instructing the body to create a safe fragment of a virus, which sets off an immune reaction against specific illnesses.
“Think about the [total addressable market] Moderna is going after – we’re going to be one of the most important vaccine companies in the world,” he said.
However, before Moderna's pipeline pays off, time will tell.
The company stated that it anticipates revenue to drop to $4 billion in 2024 before growing again in 2025 in its third-quarter earnings report in November. During a November earnings call, officials stated that it anticipates breaking even in 2026.
The most recent attempts by Moderna to enter late-stage trials offer the business substantial prospects. The most prevalent cause of the stomach flu, norovirus, is presently not preventable with a vaccine. Moderna estimates that the virus causes over 200,000 fatalities annually and significant medical expenses.
In a phase I trial, the business looked at two distinct norovirus injection candidates on over 600 American patients between the ages of 18 and 49 and 60 and 80.
A preliminary research revealed that a single dosage of the trivalent vaccine mRNA-1403, which targets three strains of the norovirus, produced a potent immune response at all dose levels. Additionally, the shot's safety profile was "clinically acceptable."
According to Moderna, the injection will now be sent to a phase three trial. As per the business, the yearly market value of norovirus vaccines ranges from $3 billion to $6 billion.
Moreover, there are currently no vaccines authorised to fend off the Epstein-Barr virus. More than 90% of cases of infectious mononucleosis, also referred to as mono, are caused by it. Mono is a contagious virus that can produce fever, sore throat, and persistent fatigue.
A greater risk of some malignancies is linked to both the virus and mono. Additionally, Moderna claims that the virus raises a patient's chance of acquiring multiple sclerosis by a factor of 32. The hallmark of that illness is the immune system eroding the nerves' protective sheath.
“It’s a big issue for teenagers. There are sometimes kids who have to redo a year of high school or college, which is a big waste of your life,” Bancel said. “But it has also been associated with multiple sclerosis, which is a terrible disease affecting mostly women ... so we think we could prevent that.”
Moderna has been working on two injections that are intended to treat various Epstein-Barr virus-related ailments. This includes mRNA-1189, a vaccine intended to prevent mono, which will proceed to a phase three research following encouraging early stage trial results.
The vaccine was tested in a phase I trial on American patients aged 12 to 30. According to the study, the injection elicited an immunological response against mono and was generally well tolerated at all dose levels.
Another vaccine that Moderna is working on is called mRNA-1195, and it's intended to treat solid organ transplant recipients' multiple sclerosis and a particular kind of lymphoma. The company reports that enrollment in a phase one trial for the vaccine is complete.
According to Bancel, the Epstein-Barr virus is anticipated to be "a several billion dollar market" by the corporation.
Shingles and chickenpox are both caused by the varicella-zoster virus. Due to their weakened immune systems, older persons are more susceptible to blister-like, unpleasant, and itchy rashes. The Centres for Disease Control and Prevention estimate that one in three adults in the United States will experience shingles at some point in their lives.
In an early- to mid-stage experiment, Moderna examined its vaccine against the virus, mRNA-1468, in healthy people 50 years of age and above in the United States.
The vaccine, according to the business, was typically well tolerated by patients and produced a significant immune response one month following the second dose.
Later this year, more information from that ongoing trial will be accessible.
According to Moderna, the varicella-zoster virus could have a $5–$6 billion yearly market.
(Source:www.medium.com)
The biotech business revealed encouraging results from three experimental vaccines against different viruses. According to the corporation, such photos are being moved to final stage studies.
With the global demand for Covid shots declining, Moderna desperately needs to have various products on the market, and this update takes them one step closer to that goal. The company's sole product that is sold commercially is the Covid jab.
The vaccination has long been associated with Moderna's stock, which saw a nearly 45% decline in value last year. However, following the developments, the company's shares closed 3% higher.
During its fifth annual "Vaccines Day," an investor event in Boston centred on the company's vaccine portfolio, Moderna will map out its post-Covid future.
The anticipated total addressable market for infectious disease injections in that industry is $52 billion, comprising of $27 billion for respiratory vaccines and over $25 billion for latent doses and other immunisations.
Latent viruses are a type of virus that can exist inside individuals for extended periods of time without showing any symptoms, but they can eventually "reactivate" and cause major health issues. In an interview, Moderna CEO Stéphane Bancel stated that they represent a significant unmet demand that Moderna can address.
"Once those viruses enter your body, they stay there forever," he stated, noting that several of the latent viruses, including several that Moderna is aiming to eradicate, have no recognised vaccinations.
At the presentation on Wednesday, the business will provide updated clinical trial data on the three vaccinations, some of which are against latent viruses.
A vaccination against the highly contagious norovirus, which causes vomiting and diarrhoea, a vaccination against the Epstein-Barr virus, a common herpes virus that can cause contagious infections and is linked to certain cancers, and a vaccination against a virus that causes shingles and chickenpox are among those vaccinations.
Additionally, Moderna will talk about other developments in its vaccine business. The business stated that it plans to share data on two of the five more injections it has in late-stage clinical studies this year. This contains a shot against the cytomegalovirus, or CMV, another prevalent herpes virus, as well as a combo vaccine against Covid and the flu.
A vaccine against the respiratory syncytial virus, or RSV, is one of the other vaccines under late-stage development and is anticipated to receive regulatory approval in the United States in May.
A revised and enhanced version of Moderna's Covid shot is also included. In a late-stage clinical trial, the company said on Tuesday that its "next-generation" Covid injection elicited a better immune response against the virus than its existing vaccine on the market.
The flu vaccine developed by the business is also undergoing phase three trials.
Additionally on Wednesday, Moderna said that it has just joined up with Blackstone Life Sciences, a division of The Blackstone Group that provides private equity, to provide capital for both development and commercialization. Moderna's flu vaccination programme will be advanced with up to $750 million from Blackstone, with low single-digit royalties and "a return based on commercial milestones."
Bancel claimed that the Covid vaccine's messenger RNA platform "is working so well" against various illnesses. The way mRNA technology functions is by instructing the body to create a safe fragment of a virus, which sets off an immune reaction against specific illnesses.
“Think about the [total addressable market] Moderna is going after – we’re going to be one of the most important vaccine companies in the world,” he said.
However, before Moderna's pipeline pays off, time will tell.
The company stated that it anticipates revenue to drop to $4 billion in 2024 before growing again in 2025 in its third-quarter earnings report in November. During a November earnings call, officials stated that it anticipates breaking even in 2026.
The most recent attempts by Moderna to enter late-stage trials offer the business substantial prospects. The most prevalent cause of the stomach flu, norovirus, is presently not preventable with a vaccine. Moderna estimates that the virus causes over 200,000 fatalities annually and significant medical expenses.
In a phase I trial, the business looked at two distinct norovirus injection candidates on over 600 American patients between the ages of 18 and 49 and 60 and 80.
A preliminary research revealed that a single dosage of the trivalent vaccine mRNA-1403, which targets three strains of the norovirus, produced a potent immune response at all dose levels. Additionally, the shot's safety profile was "clinically acceptable."
According to Moderna, the injection will now be sent to a phase three trial. As per the business, the yearly market value of norovirus vaccines ranges from $3 billion to $6 billion.
Moreover, there are currently no vaccines authorised to fend off the Epstein-Barr virus. More than 90% of cases of infectious mononucleosis, also referred to as mono, are caused by it. Mono is a contagious virus that can produce fever, sore throat, and persistent fatigue.
A greater risk of some malignancies is linked to both the virus and mono. Additionally, Moderna claims that the virus raises a patient's chance of acquiring multiple sclerosis by a factor of 32. The hallmark of that illness is the immune system eroding the nerves' protective sheath.
“It’s a big issue for teenagers. There are sometimes kids who have to redo a year of high school or college, which is a big waste of your life,” Bancel said. “But it has also been associated with multiple sclerosis, which is a terrible disease affecting mostly women ... so we think we could prevent that.”
Moderna has been working on two injections that are intended to treat various Epstein-Barr virus-related ailments. This includes mRNA-1189, a vaccine intended to prevent mono, which will proceed to a phase three research following encouraging early stage trial results.
The vaccine was tested in a phase I trial on American patients aged 12 to 30. According to the study, the injection elicited an immunological response against mono and was generally well tolerated at all dose levels.
Another vaccine that Moderna is working on is called mRNA-1195, and it's intended to treat solid organ transplant recipients' multiple sclerosis and a particular kind of lymphoma. The company reports that enrollment in a phase one trial for the vaccine is complete.
According to Bancel, the Epstein-Barr virus is anticipated to be "a several billion dollar market" by the corporation.
Shingles and chickenpox are both caused by the varicella-zoster virus. Due to their weakened immune systems, older persons are more susceptible to blister-like, unpleasant, and itchy rashes. The Centres for Disease Control and Prevention estimate that one in three adults in the United States will experience shingles at some point in their lives.
In an early- to mid-stage experiment, Moderna examined its vaccine against the virus, mRNA-1468, in healthy people 50 years of age and above in the United States.
The vaccine, according to the business, was typically well tolerated by patients and produced a significant immune response one month following the second dose.
Later this year, more information from that ongoing trial will be accessible.
According to Moderna, the varicella-zoster virus could have a $5–$6 billion yearly market.
(Source:www.medium.com)
Homepage
Send to a friend
Printable version
Share
